TOSHIBA
27.8.2020 07:02:11 CEST | Business Wire | Press release
Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has launched three photorelays: “TLP3407SRA ,” “TLP3475SRHA ” and “TLP3412SRHA ,” that are the industry-smallest[1] voltage driven photorelays with an extended operating temperature rating of 125°C.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005815/en/
Raising the maximum operating temperature rating from 110°C to 125°C allows the photorelays to be mounted in high temperature areas, and makes it easier to secure required temperature design margins for equipment. The S-VSON4T package has the industry-smallest[1] mounting area of 2.9mm² .This will contribute to reducing PCB size or to increasing the number of photorelays in an existing layout in applications such as semiconductor testers, probe cards and other devices.
Applications
- Semiconductor testers (memory, SoC and LSI, etc.)
- Probe cards
- Burn-in equipment
- Measuring instruments (oscilloscope, data logger, etc.)
Features
- S-VSON4T, the industry’s first[1] packaging with a minimal mounting area and maximum operating temperature of 125°C: Mounting area 2.9mm2 (typ.)
- Low input power consumption drive: 3.3mW[2] (max) @VIN =3.3V (TLP3407SRA)
Main Specifications
(@Ta =25℃) |
||||
Part number |
||||
Package |
Name |
S-VSON4T |
||
Size typ. (mm) |
2.0×1.45 |
|||
Height typ.(mm) |
1.3 |
|||
Recommended
|
Applied input forward voltage VIN typ. (V) |
3.3 |
3.3 |
3.3 |
Built-in resistance typ. (Ω) |
4000 |
600 |
600 |
|
Absolute maximum ratings |
OFF-state output terminal voltage VOFF (V) |
60 |
60 |
60 |
ON-state current ION (A) |
1 |
0.4 |
0.4 |
|
ON-state current (pulsed) IONP (A) |
3 |
1.2 |
1.2 |
|
Operating temperature Topr (℃) |
-40 to 125 |
|||
Coupled
|
Limited LED current ILIM(LED) max (mA) (@VIN ) |
1
|
- |
- |
Trigger LED current IFT max (mA) |
0.2 |
2 |
2 |
|
Operating voltage VFON max (V) |
3 |
3 |
3 |
|
ON-state resistance RON max (Ω) |
0.3 |
1.5 |
1.5 |
|
Electrical characteristics |
Output capacitance COFF typ. (pF) |
80 |
12 |
20 (max) |
OFF-state current IOFF max (nA) (@VOFF ) |
1 (@50V) |
1 (@50V) |
1 (@50V) |
|
Switching characteristics |
Turn-on time tON max (ms) |
20 |
0.5 |
0.5 |
Turn-off time tOFF max (ms) |
1 |
0.2 |
0.2 |
|
Isolation characteristic |
Isolation voltage BVS min (Vrms) |
500 |
500 |
500 |
Sample Check & Availability |
||||
Notes:
[1] For photorelays where maximum operating temperature rating is 125°C, according to a survey by Toshiba (as of August 25, 2020).
[2] Applied input forward voltage × maximum limited LED current=3.3V×1mA
Follow the link below for more on the new photocouplers.
TLP3407SRA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3407SRA
TLP3475SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3475SRHA
TLP3412SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3412SRHA
Follow the link below for more on Toshiba’s photorelay lineup.
https://toshiba.semicon-storage.com/ap-en/semiconductor/product/optoelectronics/photorelay-mosfet-output.html
To check availability of the new products at online distributors, visit:
TLP3407SRA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3407SRA.html
TLP3475SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3475SRHA.html
TLP3412SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3412SRHA.html
Customer Inquiries:
Optoelectronic Device Sales & Marketing Dept.
Tel: +81-3-3457-3431
https://toshiba.semicon-storage.com/ap-en/contact.html
* Company names, product names, and service names may be trademarks of their respective companies.
* Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.
About Toshiba Electronic Devices & Storage Corporation
Toshiba Electronic Devices & Storage Corporation combines the vigor of a new company with the wisdom of experience. Since becoming an independent company in July 2017, the company has taken its place among the leading general devices companies, and offers its customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.
Its 24,000 employees around the world share a determination to maximize the value of its products, and emphasize close collaboration with customers to promote co-creation of value and new markets. The company looks forward to building on annual sales now surpassing 750-billion yen (US$6.8 billion) and to contributing to a better future for people everywhere.
Find out more about Toshiba Electronic Devices & Storage Corporation at https://toshiba.semicon-storage.com/ap-en/top.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
